Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
LGND
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.88B
Close$
$65.89
77.2% downside
Current Fair Value
77.2% downsideOvervalued by 77.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.88 Billion |
|---|---|
| Enterprise Value | $5.64 Billion |
| Dividend Yield | $0.46 (-) |
| Earnings per Share | $6.44 |
| Beta | 1.07 |
| Outstanding Shares | 20,063,000 |
Return
| Return on Equity | 19.07% |
|---|---|
| Return on Assets | 8.44% |
| Return on Invested Capital | 10.27% |
Valuation & Multiples
| P/E Ratio | 29.29 |
|---|---|
| PEG | 3.25 |
| Price to Sales | 20.63 |
| Price to Book Ratio | 6.02 |
| Enterprise Value to Revenue | 19.43 |
| Enterprise Value to EBIT | 25.68 |
| Enterprise Value to Net Income | 30 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$2.00
Average shareholder expectationRevenue Estimate
$63.99 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$2.62
Average shareholder expectationRevenue Estimate
$78.35 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1765▼ 64.97% |
|---|---|
| Total Calls | 1,700▼ 95.95% |
| Total Puts | 300▼ 99.14% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 44.31%▼ 61.14% |
|---|---|
| Total Invested | $2.78B▼ 32.92% |
| Investors Holding | 195▼ 171.00% |
ESG Score
No data
About Ligand Pharmaceuticals, Inc.
CEO: John Higgins